THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
* Issues related to the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| BRENDAN DEVINE | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Health Issues HCR
* Issues related to surprise billing law and regulation. * Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. * Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. * Issues related to S. 113, the Prescription Pricing for the People Act, and S. 127, the Pharmacy Benefit Manager Transparency Act. * Issues related to removing barriers to biosimilar medicine access. * Issues related to insulin pricing. * Issues related to mental health coverage, workforce, and mental health parity. * Issues related to Quality-Adjusted Life Year (QALY) or similar metrics in health coverage legislation. * S. 1001, Issues related to the Telehealth Expansion Act. * Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| KATHRYN GALLAGHER New | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Defense DEF
* Pharmacy issues related to TRICARE and the Fiscal Year 2024 National Defense Authorization Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| KATHRYN GALLAGHER New | — |
| CHRISTOPHER HARTMANN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.